Physician profile
Leon Casals
NPI 1699710368
$5,229.20
in general payments reported to CMS, 2019-2025
26 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $1,279 · 2021: $869 · 2022: $864 · 2023: $464 · 2024: $362 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.06 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $961.76 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $959.94 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $379.87 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $309.89 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.46 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $269.46 | 2020-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.18 | 2020-2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $216.79 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $200.11 | 2020 | |
| Abbvie INC. | $187.01 | 2019-2024 | |
| Amarin Pharma, INC. | $184.78 | 2019-2021 | |
| Astellas Pharma US INC | $173.99 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $167.50 | 2019-2021 | |
| Abbott Laboratories | $146.59 | 2021-2022 | |
| Amgen INC. | $117.36 | 2019-2023 | Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $76.37 | 2025 | Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $73.41 | 2019 | |
| Allergan, INC. | $65.15 | 2019-2020 | |
| Medtronic Minimed, INC. | $56.71 | 2020 | |
| Dexcom, INC. | $29.72 | 2021-2022 | |
| Aytu Biopharma, INC. | $27.33 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $26.96 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $19.86 | 2022 | |
| Pfizer INC. | $16.10 | 2019 | |
| Eisai INC. | $14.29 | 2021 | |
| Genentech USA, INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Casals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.